OUR PLATFORM
NeoVac is a platform company advancing next-generation lipid nanoparticle (LNP) technology.
Our technology, allows for improved safety, adaptable immunogenicity, and specific organ targeting.
Our technology is applicable across multiple therapeutic and preventive routes of intervention, including viral and bacterial vaccines, cancer immunotherapy, and autoimmune diseases.
01
Platform Status
NeoVac’s platform is applicable across a wide range of applications, including targeted cancer immunotherapy, viral and bacterial infections, as well as malaria and inflammatory IBD. Programmes span R&D and preclinical stages, with clinical validation in COVID-19, highlighting the breadth of the technology.
02
Platform Application
Cancer Immunotherapy
NeoVac’s LNP platform can be combined with ligands that specifically bind to receptors at target cells, addressing the poor targeting of conventional mRNA-LNPs. This approach enables cancer immunotherapy with reduced dosing, an improved toxicity profile and alternative routes of administration.
03
Platform Application
Shingles
NeoVac is developing an mRNA shingles vaccine that is efficacious, safer and more affordable. The programme addresses the limitations of current options, aiming to deliver a low-cost vaccine for a large, fast-growing global market.
04
Platform Application
Bacterial Infections
NeoVac is pioneering the first-ever mRNA vaccine for plague using its proprietary LNP platform, addressing a Category A biothreat with no approved vaccines, growing antimicrobial resistance, and rising risk of outbreaks in endemic and under-resourced regions.
05
Platform Application
Malaria
NeoVac is advancing a dual-stage PEV-TBV mRNA vaccine for malaria that both prevents infection and blocks transmission, delivering a deployable solution to protect forces in endemic regions and bolster global health security against a disease causing hundreds of millions of cases and over 600,000 deaths each year.